Research Roundup

Debbie Rigby rounds up the latest research news Tirzepatide for maintenance of bodyweight reduction in people with obesity (SURMOUNT-MAINTAIN)   The SURMOUNT-MAINTAIN trial found that maintaining tirzepatide at the highest tolerated dose helped sustain weight loss and related health benefits. Lowering the dose to 5 mg may be a useful alternative to stopping treatment, though individual responses can